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ABSTRACT   
A frequent quantification of drugs concentrations in plasma of patients subject to chemotherapy is seldom performed, 
mostly because the standard methods (Gas or Liquid Chromatography coupled with Mass Spectroscopy) are expensive 
and time consuming.  
In this paper we report the approach pursued in one of the research units of the EU project RAMAN4CLINICS to tackle 
the problem of a low cost, time adherent quantification of drugs used for oncological patients using a Surface Enhanced 
Raman Scattering (SERS) spectroscopy.  
More specifically, the issues concerning the repeatability of the nanostructured substrates will be presented and some 
promising results to increase the selectivity of the measures toward specific drugs will be discussed, with examples 
concerning one cytotoxic agent, Irinotecan and one kinase inhibitor, Sunitinib. 
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1. INTRODUCTION  
Chemotherapeutic drugs are expensive, have rather heavy side effects on patients, and are usually effective in a very 
narrow therapeutic window of plasmatic concentrations. All these factors point to the opportunity to optimize their use, 
adjusting in real time the dosage of the drugs administered to the patients in what is called Therapeutic Drug Monitoring 
(TDM). Unfortunately, the golden standard for the quantification of drugs in the course of chemotherapeutic treatments 
is Mass Spectroscopy coupled with High Performance Liquid Chromatography (HPLC-MS), which is both time 
consuming and expensive. Consequently, TDM is seldom performed on oncological patients and the administration of 
the drugs is grossly adjusted on the base of the side effects as reported by the patients or as inferred from the routine 
blood analysis. Simple, rapid and low-cost methods for chemotherapeutic drugs quantification are thus needed to 
effectively implement TDM. In this contribution we outline an approach that we are pursuing to reach this goal by using 
a combination of Raman spectroscopy, nanotechnology and chemometrics. Raman spectroscopy in particular has long 
attracted the interest of the medical community as an analytical tool and it is at the heart of a European initiative called 
RAMAN4CLINICS, aimed at introducing Raman spectroscopy in clinical practice. One of the activities of 
RAMAN4CLINICS is specifically devoted to TDM, and the approach used constitutes the backbone of this contribution. 
When molecules are absorbed on nanostructured metal surfaces, their Raman spectral signature is highly enhanced: this 
effect is known as Surface Enhanced Raman Scattering (SERS), where the enhancement is up to billions of time (with 
respect to the spectrum of the same analyte with the same concentration but without adsorption on the nanostructured 
metal surface). The strong SERS enhancement can be exploited to obtain information from chemotherapeutic drugs in 
concentration of interest for the oncological patients, typically from nanomolar to micromolar. SERS approaches for 
drug quantification have been previously tried, also using a separation step different than HPCL (e.g. TLC) before SERS 
analysis [1]. Once the SERS spectra are obtained, several chemometric techniques can be applied to obtain calibration 
curves/models capable of establishing appropriate relationships between instrumental responses and the concentration of 
the drugs of interest in blood/plasma/serum of the patients, which is the ultimate goal. 
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serum/plasma components may contribute to the measured intensity at a specific Raman shift, making often impossible 
to differentiate an analyte-specific signal from an interfering one when looking only at one point of a data spectrum. An 
alternative is a multivariate calibration, using multiple responses simultaneously (e.g., the response at a range of Raman 
shifts, or over the entire range collected, to calculate concentrations), which may overcome most of the limitations of 
univariate calibration. In figure 5 we report promising preliminary results of Methotrexate (MTX) quantification in 
diluted human serum with SERS substrate and chemometric analysis: multivariate calibration models built using partial 
least-squares regression (PLSR) were compared with univariate calibration. The PLS model outperformed the univariate 
model. 
 
 
Figure 5 Diagnostic plots from univariate and multivariate calibration for SERS spectra of MTX collected in diluted human 
serum. A: (o) calibration data for the univariate calibration, confidence bands (broken blue line) and prediction bands 
(broken red line). B: results from the 100 repetitions in Repeated Double Cross Validation (RDCV) for a Partial Least 
Square Regression (PLSR) are reported in orange; the means of 91 predictions are reported in yellow. SERS spectrum 
of MTX 10 μM and the chemical structure of MTX are reported for reference. All spectra were collected on 
functionalized Au solid SERS substrate using an excitation at 785 nm.  
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3. CONCLUSIONS 
In this work, we present solid SERS substrates of Au and Ag NPs, developed with a simple dip-coating method, able to 
quantify anticancer drugs in a model PBS solution and in a complex matrix, such as diluted human serum, as well if the 
SERS technique is combined with multivariate calibration. However, the substrates sensitivity its still too low to detect 
some anticancer agent, such as Irinotecan, in biofluids in therapeutic plasmatic values and moreover, the observed 
prediction error obtained with multivariate calibration it is still too high if compared with the value provided by 
established reference methods. Thus, an increase in selectivity and sensitivity of the SERS substrates is necessary. For 
this reason, we present preliminary results of substrates functionalization using the host-guest supramolecular approach, 
which increase the substrates sensitivity, at least in a PBS solution, of Irinotecan concentration detection of 2 orders of 
magnitude. Moreover, we show the advantages of multivariate regression methods with respect to univariate calibration, 
in the case of MTX.  
Overall, this contribution reports the logical procedure used in one of the approaches of the Working Group 1 
(Therapeutic monitoring of antitumoral drugs and antibiotic in body fluids) of the EU COST (European Cooperation in 
Science and Technology) action RAMAN4CLINICS. 
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